Every AI newsletter asks investors to ask questions on the investor interaction platform: in March 15, 2022, the national health and Health Commission and the State Administration of traditional Chinese medicine jointly issued the New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth), of which Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) Xuebijing is in. Now the epidemic situation is very serious in China. Will the company make an overtime product?
Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) ( Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) . SZ) said on the investor interaction platform on April 2 that the current production can meet the market demand.
